Objective: To evaluate the midterm hemodynamic performance and clinical outcomes of the Trifecta aortic pericardial valve.
See Editorial Commentary page 570.
The use of bioprosthetic aortic heart valves has increased steadily in recent years as a result of increasing numbers of elderly patients undergoing aortic valve replacement, as well as anticipated improved durability of pericardial prostheses. 1 The availability of a bioprosthetic aortic heart valve with excellent hemodynamic performance and durability is attractive particularly for younger patients and those with a small aortic root. By incorporating experience from previous valve designs and leveraging improvements in tissue processing, the Trifecta aortic pericardial valve (St Jude Medical, St. Paul, Minn) was introduced into commercial use in 2010. Mid-term results on the safety and performance of the valve are reported based on a cohort of patients from the premarket approval study who consented to participate in longerterm follow-up.
MATERIALS AND METHODS Study Design
To evaluate the mid-term clinical outcomes of the Trifecta valve, 710 eligible patients from 11 investigational sites were followed in this multicenter, prospective, nonrandomized, observational study. Valves were implanted with the use of standard methods (Video 1) between 2007 and 2009 as part of the premarket approval study (ClinicalTrials.gov number, NCT00475709) with inclusion/exclusion criteria as previously described (Appendix E1). 2 The 11 participating institutions consist of 9 investigational sites in the United States and 2 sites in Canada (Appendix E2). At each site, there were 2 or more primary surgeons who performed implants. After the premarket study was closed, 434 patients at these 11 sites moved on to participate in either a postapproval study (n ¼ 245) mandated by the Food and Drug Administration or a voluntary postmarket long-term follow-up study (n ¼ 189). The postapproval and long-term follow-up studies were both sponsored by St Jude Medical and registered with ClinicalTrials.gov, NCT01514162 and NCT01593917 ( Figure E1 ). The appropriate institutional review board approval was obtained at each center, and all patients gave written informed consent to participate in each study.
The Trifecta valve is a trileaflet stented pericardial valve designed for supra-annular placement in the aortic position. The valve is fabricated via a polyester-covered titanium stent. The stent, excluding the sewing cuff, is then covered with porcine pericardial tissue. This covering is designed to provide protection from mechanical wear by allowing only tissue-to-tissue contact during valve function. A silicone insert in the polyester sewing cuff is contoured slightly to conform to the shape of the native annulus. The valve leaflets are fabricated from bovine pericardium.
The porcine and bovine pericardium are preserved and cross-linked in glutaraldehyde. Glutaraldehyde, formaldehyde and ethanol are used in the valve sterilization process. In addition, the Trifecta valve is processed with an ethanol-based anticalcification treatment (Linx AC; St Jude Medical) that in animal studies has demonstrated resistance to calcification. 3 There are no clinical data currently available that evaluate the long-term impact of the anticalcification tissue treatment in humans.
In the premarket approval study, the instructions for use recommended a postoperative antithrombotic regimen consisting of long-term, low-dose aspirin, unless contraindicated. A recommendation also is made for long-term anticoagulation therapy, unless contraindicated, in patients with risk factors for thromboembolism.
Follow-up
In the premarket approval study (NCT00475709) follow-up occurred at hospital discharge and during clinic visits at 6 months and at each year postimplant until study closure. Patients in the postapproval study (NCT01514162) continued to be followed on an annual basis with a clinic visit, whereas patients in the long-term follow-up study (NCT01593917) were followed annually with a clinic visit except for years 4 and 6, when a telephone follow-up was performed. Each clinic visit consisted of a transthoracic echocardiogram and assessments for New York Heart Association (NYHA) functional classification, serious adverse events, and general clinical status. An independent core laboratory assessed all echocardiograms, and an independent clinical events committee adjudicated adverse events. Over an interval of 6 years, 701 patients underwent 3751 clinic visits with a total of 3698 echocardiograms (98.6%) performed. 4 Events were classified as occurring early (within 30 days of implant) or late (!31 days after implant).
Statistical Analysis
Statistical analyses were performed with SAS software version 9.3 (SAS institute Inc, Cary, NC). Continuous variables are presented as mean AE standard deviation and range (minimum, maximum) and categorical variables as frequencies and percentages. For late adverse events, KaplanMeier analyses were used to summarize the time to first adverse events. Linear mixed models (SAS PROC MIXED) were used to evaluate the change over time of the hemodynamic measurements. [5] [6] [7] As part of this evaluation, the skewed hemodynamic measurements of aortic valve gradient, effective orifice area, and effective orifice area index were transformed logarithmically to achieve a more normal distribution of dependent variables. The models also include a transformation of implant duration and valve size as fixed effects, along with a random intercept and a random slope for the implant duration (Table E1 ). Ordinal longitudinal mixed models (SAS PROC NLMIXED) were used to evaluate the change over time of the ordinal repeated measures of NYHA class and aortic regurgitation grade. 7 The ordinal longitudinal mixed models include the continuous variable of implant duration as a fixed effect and a random intercept (Table E2) .
RESULTS
The mean age of the 710 patients was 72.4 AE 9.3 years, with 152 patients (21.4%) having an age !80 years. Baseline patient demographics and operative details for these patients are detailed in Table 1 and Table 2 . Indications for aortic valve replacement included stenosis in 366 patients (51.6%), regurgitation in 45 patients (6.3%), and mixed 
NYHA Classification
The trend of NYHA functional classification over time is shown in Figure 1 . At 6 years of clinical follow-up, 90.6% of patients were NYHA class I. A further 5.2% of patients were 
Clinical Outcomes
Kaplan-Meier analysis of freedom from all-cause mortality is presented in Figure 3 . Early ( 30 days postimplant) mortality occurred in 11 patients (1.5%), and there were 57 late (!31 days) deaths, yielding a linearized mortality rate of 1.98% per late patient-year. At 3 years, cumulative freedom from overall mortality was 93.0%, and freedom from valve-related mortality was 99.2%. The same measures at 6 years (157 patients at risk) were 87.9% and 98.3%, respectively.
Clinical outcomes after aortic valve replacement are shown in Table 3 . There were 52 (7.3%) instances of early major bleeding, of which 39 (5.5%) were from mediastinal or thoracic sites with 27 (3.8%) requiring surgical intervention. At 1 year, 3 years, and 6 years postimplant, freedom from all major bleeding events was 91.7%, 89.3%, and 83.5%, respectively. Among the 51 patients with late bleeding events, 20 patients (39.2%) were receiving anticoagulation at the time of the event. There were no episodes of valve thrombosis or clinically significant hemolysis throughout follow-up.
Preoperatively, 16.9% of patients had a history of atrial fibrillation/flutter, with 11.0% of patients being on chronic oral anticoagulation therapy. The predominant underlying rhythm before aortic valve replacement was atrial fibrillation/flutter in 8.5% (60/710). New-onset atrial fibrillation requiring postoperative treatment occurred in 36.6% (238/650). New permanent pacemakers were implanted within 30 days postoperatively in 43 patients (6.1%), which include 5 patients with a history of atrial fibrillation who underwent a concomitant maze or ablation procedure. At hospital discharge, oral anticoagulation therapy consisting of warfarin was prescribed to 22.5% (158/701) of patients, which was decreased to 16.6% (110/662) at 6 months after aortic valve replacement. Eighty-five percent of the patients (n ¼ 134) being discharged on oral anticoagulation therapy were being treated for atrial fibrillation. In the remainder of patients discharged on oral anticoagulation therapy (n ¼ 24; 15%), the indication for anticoagulation therapy was not specified; however, in 8 of these patients, oral
anticoagulation therapy was already prescribed preoperatively. Among patients who were not discharged on oral anticoagulation therapy, 96.3% (523/543) were discharged on either aspirin or another antiplatelet agent.
Freedom from all embolic events was 96.0%, 94.6%, and 93.5% at 1 year, 3 years, and 6 years postimplant, respectively. Freedom from nonstructural dysfunction and paravalvular leak at 6 years was 98.6% and 98.9%, respectively. Freedom from endocarditis was 99.4%, 99.3%, and 98.9% at 1 year, 3 years, and 6 years postimplant, respectively.
There was one explant that occurred 1 day after implant as a result of a suture injury to a congenitally malpositioned intramural coronary artery. At the time of valve explant, there was no evidence of valve malfunction, and it was determined that the coronary artery was not obstructed by the prosthesis.
Durability
There were a total of 18 reoperations resulting in valve explant that occurred beyond 30 days postimplant. There were no cases of valve repair or transcatheter valve-in-valve procedures performed in any of the patients. The explants were attributable to endocarditis (n ¼ 3), nonstructural valve dysfunction (n ¼ 4), and structural valve deterioration (SVD; n ¼ 11). Freedom from reoperation was 99.4%, 98.6%, and 96.0% at 1 year, 3 years, and 6 years postimplant, respectively. Kaplan- Meier analysis of freedom from reoperation due to SVD is presented in Figure 4 . Among the 11 cases of SVD calcification or fibrous thickening of the leaflets was present in 10 of the cases, and a noncalcific leaflet tear was present in 1 case. The noncalcific leaflet tear occurred in a younger patient (age 49 years) who had a native bicuspid aortic valve. Reoperations due to SVD were for valve sizes 21 mm (3 valves), 23 mm (4 valves), and 25 mm (4 valves).
Patients who underwent reoperation due to SVD were 64.1 AE 11.8 years of age, with none of these patients having renal failure. When limiting the analysis to patients with an age !65 years, the freedom from reoperation due to SVD was 98.3% at 6 years of follow-up. When we included all patients with SVD (15 total with or without reoperation), the freedom from SVD was 95.7% at 6 years. Freedom from reoperation due to SVD in patients with an age <65 years was 93.8% at 6 years of follow-up.
DISCUSSION
This prospective, multicenter follow-up study demonstrates that aortic valve replacement with the Trifecta valve is associated with excellent hemodynamic performance and satisfactory durability through 6 years of follow-up. An association between hemodynamic performance and durability was evaluated recently in a large, single-center study involving a pericardial tissue heart valve. 8 Valves that had a greater postoperative transvalvular gradient and that demonstrate a more rapid increase in transvalvular gradients were more likely to develop SVD over time. A gradual increase in the transvalvular gradient of 0.5 to 1 mm Hg per year is a normal finding during the initial 10 years after implantation of a bioprosthetic heart valve, and is considered not clinically significant. 9 In the absence of anticalcification treatment or when the valve is implanted in younger patients or patients with renal failure, however, the increase in transvalvular gradient may become more rapid (>2 mm Hg/y) with an increased likelihood of developing SVD. 10, 11 Mechanisms responsible for the postoperative increase in transvalvular gradient may include an immunological reaction with deposition of platelets and subsequent formation of a fibrin layer with thickening of the leaflets. Excessive formation of pannus also may contribute to the process by restricting leaflet motion. In some cases, this biological reaction may progress to leaflet thrombosis, and ultimately may result in leaflet degeneration in the form of fibrosis or calcification. 12 An interruption of antithrombotic therapy also may be a predisposing factor. 13 In this study, all 11 patients who underwent reoperation due to SVD were prescribed antiplatelet therapy at hospital discharge without receiving oral anticoagulation therapy postoperatively. Although data from the Danish National Patient Registry support a benefit of using anticoagulation during the first 6 months after bioprosthetic aortic valve replacement, there is discordance regarding this information between the European and American College of Cardiology/American Heart Association guidelines. 12, 14 It remains uncertain whether a period of more intensive antithrombotic therapy postoperatively may result in fewer cases of early SVD.
The Trifecta valve was shown to have excellent hemodynamic performance both at rest and during exercise through the first year postimplant. [15] [16] [17] The excellent hemodynamic performance has been shown to persist through 3-years of follow-up, 18 and with this mid-term follow-up study the results are extended to 6 years of follow-up. Hemodynamic performance becomes most clinically relevant when a small aortic root is encountered and a decision is made to implant a small valve size without enlarging the aortic root. In this study at 5 years postimplant, the mean transvalvular gradients for the 19-mm and 21-mm Trifecta valve sizes were 14.3 and 10.5 mm Hg, respectively. In comparison, Banbury and colleagues 9 report at 5-years postimplant mean transvalvular gradients of 18 and 14 mm Hg for the 19 mm and 21 mm sizes of the Carpentier-Edwards PERIMOUNT valve (Edwards Lifesciences, Irvine, Calif), respectively. Several recent studies have shown that the Trifecta valve has improved hemodynamic performance compared with the Carpentier-Edwards PERIMOUNT Magna Ease valve (Edwards Lifesciences) both at rest and during exercise, [15] [16] [17] [18] [19] and in one study involving patients with left ventricular hypertrophy there was greater regression of left ventricular mass in patients implanted with the Trifecta valve. 19 The excellent hemodynamic performance of the Trifecta valve reduces the likelihood of developing patientÀprosthesis mismatch, which is of clinical significance because patientÀprosthesis mismatch has been shown to be associated with an increase in mortality and a reduction in freedom from SVD. 20 The excellent hemodynamic performance of the Trifecta valve is achieved as a result of a valve design that allows for more complete opening of the valve using leaflets that are mounted externally onto a thin flexible titanium stent frame. Because of the excellent hemodynamic performance of the Trifecta valve, oversizing of the valve usually is not necessary to achieve the desired hemodynamic performance. 16 Although previous clinical experience with older generations of pericardial tissue valves that use an alignment stitch at the top of externally mounted leaflets have encountered challenges with respect to early failures, 22 this study demonstrates that the Trifecta valve remains durable through 6 years of follow-up. There is no alignment stitch in the design of the Trifecta valve and in vitro testing demonstrates by means of accelerated lifetime cyclic testing a fully functional valve after 1.25 billion cycles (approximately 31 years). 23 The primary mode of SVD observed in vivo in this study was fibrous thickening of the leaflets or calcific leaflet degeneration, but the observed rate was low. The observed freedom from reoperation due to SVD at 6 years of follow-up for the Trifecta valve was 97.3%. This finding compares favorably with the freedom from reoperation due to SVD observed for the CE PERIMOUNT valve, which was reported to be 97.2% at 7 years postimplant. 24 The primary mode of failure reported for the CE PERI-MOUNT valve also was fibrous-calcific leaflet deterioration.
Both the Trifecta valve and the CE PERIMOUNT valve have anticalcification treatment that reduces the likelihood of developing fibrous-calcific SVD; however, in comparison, earlier generations of the Mitroflow valve (Models 12A and LX; SORIN Group, Milan, Italy) do not have anticalcification treatment, thereby increasing the potential for early calcific leaflet deterioration. 10 When the Mitroflow Model 12A valve was used, the freedom from reoperation caused by SVD was reported by Asch and colleagues 25 to be 97.8% at 5-years post-implant. The primary failure mode reported for the Mitroflow valve was calcific deterioration.
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The evolution over time of hemodynamic parameters for the Trifecta valve demonstrates a slight increase in the percentage of valves with mild-to-severe aortic regurgitation. This is an expected finding, considering that some of the valves may develop leaflet thickening which can impact leaflet coaptation. A similar increase in the percent of valves with mild to severe aortic regurgitation is observed for the CE PERIMOUNT valve. 9 When we used the mixed model, the estimated percentages of Trifecta valves with mild, moderate, and severe aortic regurgitation at 6 years postimplant were 13.7%, 4.7%, and 2.7%, respectively. In comparison, the CE PERIMOUNT valve has estimated percentages of mild, moderate, and severe aortic regurgitation at 6 years postimplant of 24.0%, 9.7%, and 2.9%, respectively. 9 All reoperations for SVD in this study were performed with an open surgical approach rather than via a transcatheter valve-in-valve implantation procedure. The feasibility of being able to perform with a good outcome a valve-in-valve transcatheter aortic valve replacement (TAVR) in a 23-mm Trifecta valve has been demonstrated previously. 26 The procedure was performed without causing coronary artery obstruction despite having the leaflets mounted externally on the stent.
When contemplating TAVR as an alternative to primary surgical aortic valve replacement, it is important to keep in mind that surgically implanted aortic valves have a lower incidence of aortic regurgitation, and in particular a lower incidence of paravalvular aortic regurgitation. [27] [28] [29] The freedom from paravalvular leak for the Trifecta valve was 98.9% at 6 years of follow-up. In addition, the need for a postoperative permanent pacemaker is greater when performing TAVR compared with surgical aortic valve replacement. In this study for comparison, 6.1% of patients required a new permanent pacemaker implant within 30 days postoperatively. 28, 29 There are limited data available for comparison on the freedom from reoperation due to SVD in patients undergoing TAVR. 30 The 5-year data for the Edwards SAPIEN transcatheter aortic valve (Edwards Lifesciences) from the PARTNER 1 study show no cases of SVD requiring reoperation. 31 In comparison, the freedom from reoperation due to SVD for the Trifecta valve at 5 years was 99.2%; however, the patients in the PARTNER 1 study were older with an age of 83.6 AE 6.8 years.
Study Limitations
This study is limited because not all patients enrolled in the premarket study agreed to participate in longer-term follow-up. After closure of the premarket study there were 176 patients (24.8%) who declined longer-term follow-up. In addition, echocardiograms at 4 years and 6 years postimplant were not required for patients enrolled in the long-term follow-up study (NCT01593917). Although not all patients agreed to participate in longer term follow-up, there are a substantial number of patients with echocardiogram data available for analysis, making the results of this study meaningful.
CONCLUSIONS
This study demonstrates that the Trifecta valve has excellent hemodynamic performance, particularly in the smaller valve sizes, that is maintained through 6 years of follow-up. The study also demonstrates that the Trifecta valve has a low complication rate and exhibits excellent durability over 6 years of follow-up. Cardiac surgeons performing aortic valve replacement should be aware of these findings, particularly when confronted with a small aortic root. Dr Goldman. I understand that there have been reports of that valve. I think there are some features of this valve that are different in that the pericardium does have an anticalcification treatment, which is absent in the other valve, and I think that some structural deterioration may be related to the calcification, which could weaken the tissue. Also, the stents are covered in porcine pericardium, which may decrease abrasion, which also could cause structural failure. Again, I think we all have concerns about long-term durability of all these valves, and we won't know until we have further data.
Webcast
Dr Woo. The mean gradients appear to increase over time in several of the sizes. Do you have any qualitative echocardiographic data on which you might wish to elaborate?
Dr Goldman. No. The echo just showed slight increases over time. This has been reported with other pericardial valves, particularly, Banbury reported this with the Perimount valve. The pericardium does stiffen up over time, but it seems like it is not clinically significant.
Dr Woo. Finally, would you care to comment on potential limitations of this valve with its angled strut design and external wrapping with respect to future potential transcatheter valve-in-valve replacement?
Dr Goldman. We have done some valve-in-valves with this valve without having any issues with coronary obstruction, although when you put this valve in and you see it opening and it goes all the way out to the sinotubular ridge, you may have some concern with that. Again, there haven't been that many valve-in-valves with this valve, so we will have to see how it goes. But I think it could be a potential issue.
